Literature DB >> 7027892

Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension.

T Dafgärd, B Forsén, T Lindahl.   

Abstract

In a double-blind study comprising 31 patients with essential hypertension not satisfactorily controlled on hydrochlorothiazide 25 mg o.m., a fixed-ratio combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg, given as 2 tablets o.m. has been compared with hydrochlorothiazide 50 mg o.m. monotherapy. With the combination regimen a significant reduction of blood pressure was achieved while doubling of the thiazide dose did not adequately control the blood pressure. In 7 patients in the thiazide-group the therapy was changed to the combination during a follow-up period and their blood pressure was normalised. During the follow-up period, 22 patients were thus treated with the fixed combination; 50% of them were controlled on one tablet o.m. The tolerability was good in both groups and no changes were observed regarding laboratory variables except for an increase in serum uric acid in the thiazide-group. The study indicates that a fixed-ratio combination of hydrochlorothiazide 12.5 mg and metoprolol 100 mg in a dose of one or two tablets once daily is a well tolerated and more effective therapy than hydrochlorothiazide 50 mg once daily monotherapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7027892

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  2 in total

1.  Comparison of the antihypertensive effect of a double dose of metoprolol versus the addition of hydrochlorothiazide to metoprolol.

Authors:  J G Smilde
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 2.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.